West Chester-based Virpax Pharmaceuticals has signed a deal with London’s Nanomerics for exclusive, North American rights to the life sciences company’s experimental “molecular masking” spray technology platform, writes John George for the Philadelphia Business Journal.

The high-density spray would be used for the potential prevention of seasonal influenza and other viral infections.

According to Virpax CEO Anthony Mack, the company is currently working on the new prophylactic project, MMS019. This involves a nasal powder spray that is applied using a preassembled device and cartridge that propel the formula into a person’s nose. The goal is to prevent various viruses from binding to epithelial cells in the nasal cavity, as well as the upper respiratory tract.

One of the uses the spray is being developed for is to block the virus that causes COVID-19.

“We believe MMS019 can work together with current personal protective equipment to enhance our ability to help prevent the spread of respiratory viral infections and seasonal influenza,” said Mack.

With the ability to provide 24-hour protection – as shown by in-vitro testing – MMS019 would be ideal for healthcare providers, paramedics, and other front-line workers, according to Mack.

Read more about Virpax Pharmaceuticals in the Philadelphia Business Journal here.

You Might Also Like

Exton Company’s Technology Helps Wean COVID-19 Patients Off Ventilators

Paoli’s Audacity Therapeutics Aims to Raise $150 Million to Test if SARS Drugs Can Treat COVID-19

Pair of Chester County Companies Working on Potential COVID-19 Treatments